Mackenzie Financial
TCRT icon

Mackenzie Financial’s Alaunos Therapeutics TCRT Stock Holding History

Mackenzie Financial’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-77
Closed -$7K – 1541
2022
Q1 		$7K Hold
77
– – ﹤0.01% 1401
2021
Q4 		$13K Sell
77
-5
-6% -$1.1K ﹤0.01% 1418
2021
Q3 		$22K Buy
+82
New +$25.1K ﹤0.01% 1420

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Mackenzie Financial's TCRT Position: Q2 2022 in Review

Mackenzie Financial sold out of Alaunos Therapeutics (TCRT) in Q2 2022, closing a stake of 77 shares — an estimated $7K sold.

Mackenzie Financial first reported a position in TCRT in Q3 2021 and held it in 3 quarters. The position peaked at $22K in Q3 2021. 124 funds tracked by Wall St. Rank hold TCRT as of Q2 2022.

  • Mackenzie Financial reported no remaining Alaunos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Mackenzie Financial sold 77 Alaunos Therapeutics shares in Q2 2022, an estimated $7K.
  • Mackenzie Financial first reported a position in Alaunos Therapeutics in Q3 2021 and held it in 3 quarters.
  • Mackenzie Financial's Alaunos Therapeutics position peaked at $22K in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2022.

Based on Mackenzie Financial's 13F filing for Q2 2022, filed 10 Aug 2022.